{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:00:46Z","timestamp":1794002446333,"version":"4.8.0"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Importance<\/jats:title><jats:p>It is critical to identify novel biomarkers for the prediction and prognosis of rheumatoid arthritis-associated interstitial lung disease (RA-ILD).<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>The objective of the study was to investigate the predictive and prognostic significance of serum uric acid (UA) in RA-ILD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design, setting, and participants<\/jats:title><jats:p>In this multicenter retrospective cohort study, demographic data, medical history, and laboratory results of 829 RA patients were extracted from electronic medical records between December 2018 and January 2024. The cohort was divided into an RA-ILD group (<jats:italic>n<\/jats:italic> =\u202f351) and an RA-no-ILD group (<jats:italic>n<\/jats:italic> =\u202f478).<\/jats:p><\/jats:sec><jats:sec><jats:title>Main outcomes and measures<\/jats:title><jats:p>The primary endpoint was the predictive capacity of baseline UA levels for the occurrence of ILD in RA patients. The secondary endpoints were all-cause mortality and the rehospitalization rate in RA-ILD patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The univariate analysis identified elevated levels of UA as a significant risk factor for the development of ILD in RA patients (OR [95% CI]: 1.68 [1.23\u20132.28], <jats:italic>p<\/jats:italic>\u202f=\u202f0.001). The multivariate analysis confirmed that elevated levels of UA remained an independent risk factor. The subgroup analysis demonstrated a stronger predictive utility of elevated UA levels in younger RA patients (age &amp;lt; 65), particularly those with shorter disease duration and no comorbidities (OR [95% CI]: 3.66 [1.66\u20138.05], <jats:italic>p<\/jats:italic>\u202f=\u202f0.001; AUC<jats:sub>ROC<\/jats:sub>\u202f=\u202f0.718). During follow-up, RA-ILD patients with elevated UA levels exhibited significantly higher all-cause mortality (22.1% vs. 13.1%; HR [95% CI]: 1.80 [1.03\u20133.17], <jats:italic>p<\/jats:italic>\u202f=\u202f0.040) and rehospitalization rates (51.9% vs. 44.4%; HR [95% CI]: 1.41 [1.00\u20131.98], <jats:italic>p<\/jats:italic>\u202f=\u202f0.047) compared to those with lower UA levels.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion and relevance<\/jats:title><jats:p>Elevated levels of serum UA may serve as a predictive marker for ILD development in RA patients, particularly in younger individuals without comorbidities, and a prognostic indicator for increased mortality and rehospitalization rates in RA-ILD patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical trial registration<\/jats:title><jats:p><jats:uri>ClinicalTrials.gov<\/jats:uri>, identifier NCT06036537.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2025.1623557","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T05:25:22Z","timestamp":1754371522000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Serum uric acid predictive value and prognostic impact in rheumatoid arthritis\u2019 associated interstitial lung disease"],"prefix":"10.3389","volume":"12","author":[{"given":"Qiongwen","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaocheng","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huxin","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changchun","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,5]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s11926-024-01155-8","article-title":"Rheumatoid arthritis-associated interstitial lung disease (RA-ILD): update on prevalence, risk factors, pathogenesis, and therapy","volume":"26","author":"Sullivan","year":"2024","journal-title":"Curr Rheumatol Rep"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S2213-2600(22)00260-0","article-title":"Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study","volume":"11","author":"Solomon","year":"2023","journal-title":"Lancet Respir Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"e77","DOI":"10.1016\/s2665-9913(22)00380-0","article-title":"Autoantibodies against citrullinated and native proteins and prediction of rheumatoid arthritis-associated interstitial lung disease: a nested case-control study","volume":"5","author":"Kronzer","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.3390\/biomedicines10061367","article-title":"Novel biomarkers, diagnostic and therapeutic approach in rheumatoid arthritis interstitial lung disease-a narrative review","volume":"10","author":"Florescu","year":"2022","journal-title":"Biomedicine"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1080\/0886022X.2022.2036620","article-title":"Research progress on related mechanisms of uric acid activating NLRP3 inflammasome in chronic kidney disease","volume":"44","author":"Wang","year":"2022","journal-title":"Ren Fail"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1164\/rccm.200808-1274OC","article-title":"Uric acid is a danger signal activating NALP3 inflammasome in lung injury inflammation and fibrosis","volume":"179","author":"Gasse","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1038\/s41418-024-01367-6","article-title":"Gelsolin alleviates rheumatoid arthritis by negatively regulating NLRP3 inflammasome activation","volume":"31","author":"Lee","year":"2024","journal-title":"Cell Death Differ"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.3390\/molecules28041551","article-title":"Suppression of macrophage activation by sodium danshensu via HIF-1\u03b1\/STAT3\/NLRP3 pathway ameliorated collagen-induced arthritis in mice","volume":"28","author":"Wu","year":"2023","journal-title":"Molecules"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1016\/j.rmed.2012.09.003","article-title":"Diagnostic and prognostic role of biomarkers for pulmonary hypertension in interstitial lung disease","volume":"106","author":"Andersen","year":"2012","journal-title":"Respir Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1053\/j.ajkd.2021.02.335","article-title":"Changes in GFR and albuminuria in routine clinical practice and the risk of kidney disease progression","volume":"78","author":"Neuen","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"102830","DOI":"10.1016\/j.eclinm.2024.102830","article-title":"Efficacy and safety of therapeutic alpha-1-microglobulin RMC-035 in reducing kidney injury after cardiac surgery: a multicentre, randomised, double-blind, parallel group, phase 2a trial","volume":"76","author":"Zarbock","year":"2024","journal-title":"EClinicalMedicine"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1002\/art.42640","article-title":"Identification, monitoring, and management of rheumatoid arthritis-associated interstitial lung disease","volume":"75","author":"Koduri","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/sim.2980","article-title":"Sample size and optimal design for logistic regression with binary interaction","volume":"27","author":"Demidenko","year":"2008","journal-title":"Stat Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.jare.2017.03.003","article-title":"Physiological functions and pathogenic potential of uric acid: a review","volume":"8","author":"El Ridi","year":"2017","journal-title":"J Adv Res"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1007\/s10067-020-05064-w","article-title":"TGF-\u03b21 +869C\/T polymorphism increases susceptibility to rheumatoid arthritis in north Indian population","volume":"39","author":"Patel","year":"2020","journal-title":"Clin Rheumatol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"e57433","DOI":"10.7759\/cureus.57433","article-title":"Comparison of adenosine deaminase, C-reactive protein, uric acid, and rheumatoid arthritis levels in patients with rheumatoid arthritis and those without arthritis: a review","volume":"16","author":"Makhe","year":"2024","journal-title":"Cureus"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3899\/jrheum.171315.C1","article-title":"Rheumatoid arthritis-interstitial lung disease in the United States: prevalence, incidence, and healthcare costs and mortality","volume":"46","author":"Raimundo","year":"2019","journal-title":"J Rheumatol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1093\/rheumatology\/kew391","article-title":"Patterns of interstitial lung disease and mortality in rheumatoid arthritis","volume":"56","author":"Zamora-Legoff","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"9184","DOI":"10.1038\/s41598-021-88734-2","article-title":"Diagnostic delay of associated interstitial lung disease increases mortality in rheumatoid arthritis","volume":"11","author":"Cano-Jim\u00e9nez","year":"2021","journal-title":"Sci Rep"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1002\/acr.24856","article-title":"Incidence, risk factors, and mortality of clinical and subclinical rheumatoid arthritis-associated interstitial lung disease: a population-based cohort","volume":"74","author":"Samhouri","year":"2022","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1007\/s10753-022-01661-w","article-title":"Serum uric acid as a diagnostic biomarker for rheumatoid arthritis-associated interstitial lung disease","volume":"45","author":"Wang","year":"2022","journal-title":"Inflammation"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1111\/resp.13848","article-title":"Risk prediction model in rheumatoid arthritis-associated interstitial lung disease","volume":"25","author":"Kim","year":"2020","journal-title":"Respirology"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1623557\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T05:25:23Z","timestamp":1754371523000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1623557\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,5]]},"references-count":22,"alternative-id":["10.3389\/fmed.2025.1623557"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1623557","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,5]]},"article-number":"1623557"}}